Login / Signup

Structural revision of the Mcl-1 inhibitor MIM1: synthesis and biological studies on ovarian cancer cells with evaluation of designed analogues.

Hippolyte PaysantSiham HedirFrédéric JustaudLouis Bastien WeiswaldAssaad Nasr El DineAli SouliemanAli HachemNicolas ElieEmilie BrotinChristophe DenoyelleJérôme BignonFanny RoussiMarie JouanneOlivier TasseauThierry RoisnelAnne Sophie Voisin-ChiretRené GréeNicolas LevoinLaurent Poulain
Published in: Organic & biomolecular chemistry (2021)
In the area of cancer research, the development of new and potent inhibitors of anti-apoptotic proteins is a very active and promising topic. The small molecule MIM1 has been reported earlier as one of the first selective inhibitors of the anti-apoptotic protein Mcl-1. In the present paper, we first revised the structure of this molecule based on extensive physicochemical analyses. Then we designed and synthesized a focused library of analogues for the corrected structure of MIM1. Next, these molecules were subjected to a panel of in cellulo biological studies, allowing the identification of dual Bcl-xL/Mcl-1 inhibitors, as well as selective Mcl-1 inhibitors. These results have been complemented by fluorescence polarization assays with the Mcl-1 protein. Preliminary structure-activity relationships were discussed and extensive molecular modelling studies allowed us to propose a rationale for the biological activity of this series of new inhibitors, in particular for the selectivity of inhibition of Mcl-1 versus Bcl-xL.
Keyphrases
  • small molecule
  • cell death
  • anti inflammatory
  • total knee arthroplasty
  • clinical trial
  • case control
  • binding protein
  • single molecule
  • molecular docking
  • single cell
  • structure activity relationship